TWI899080B - Ｄｎａ依賴性蛋白激酶抑制劑 - Google Patents

Ｄｎａ依賴性蛋白激酶抑制劑

Info

Publication number
TWI899080B
TWI899080B TW109117346A TW109117346A TWI899080B TW I899080 B TWI899080 B TW I899080B TW 109117346 A TW109117346 A TW 109117346A TW 109117346 A TW109117346 A TW 109117346A TW I899080 B TWI899080 B TW I899080B
Authority
TW
Taiwan
Prior art keywords
methyl
mmol
pyrazolo
equiv
pyridin
Prior art date
Application number
TW109117346A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110849A (zh
Inventor
齊長河
漢忠 徐
慶北 曾
楊振帆
小林 張
Original Assignee
大陸商迪哲（江蘇）醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商迪哲（江蘇）醫藥股份有限公司 filed Critical 大陸商迪哲（江蘇）醫藥股份有限公司
Publication of TW202110849A publication Critical patent/TW202110849A/zh
Application granted granted Critical
Publication of TWI899080B publication Critical patent/TWI899080B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109117346A 2019-05-27 2020-05-25 Ｄｎａ依賴性蛋白激酶抑制劑 TWI899080B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019088573 2019-05-27
WOPCT/CN2019/088573 2019-05-27

Publications (2)

Publication Number Publication Date
TW202110849A TW202110849A (zh) 2021-03-16
TWI899080B true TWI899080B (zh) 2025-10-01

Family

ID=73551904

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109117346A TWI899080B (zh) 2019-05-27 2020-05-25 Ｄｎａ依賴性蛋白激酶抑制劑

Country Status (11)

Country Link
US (1) US20220242884A1 (https=)
EP (1) EP3976624A4 (https=)
JP (1) JP7696834B2 (https=)
CN (1) CN113924305A (https=)
AR (1) AR119018A1 (https=)
AU (1) AU2020281332B2 (https=)
BR (1) BR112021023824A8 (https=)
CA (1) CA3137598A1 (https=)
MX (1) MX2021014455A (https=)
TW (1) TWI899080B (https=)
WO (1) WO2020238900A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213460A1 (zh) * 2020-04-23 2021-10-28 山东轩竹医药科技有限公司 三并环类激酶抑制剂
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN116669741B (zh) * 2021-01-05 2025-07-22 山东轩竹医药科技有限公司 多环类激酶抑制剂
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN116023393B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023394B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
CN115322209B (zh) * 2022-07-19 2023-06-20 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN116239610B (zh) * 2023-02-23 2024-01-16 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
TW201837045A (zh) * 2016-12-20 2018-10-16 瑞典商阿斯特捷利康公司 胺基-三唑并吡啶化合物及其在治療癌症中之用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
EP1846408B1 (en) * 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CA2775009A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
WO2011134831A1 (en) * 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
US9040545B2 (en) * 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
CN103874699A (zh) * 2011-09-20 2014-06-18 赛尔佐姆有限公司 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
MX371331B (es) * 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
WO2015115673A1 (en) 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
AU2018381574B2 (en) * 2017-12-05 2022-09-15 Oscotec Inc. Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN110885331B (zh) * 2018-09-11 2021-07-09 中国药科大学 一种6-氨基-1H-吡唑并[3，4-d]嘧啶类JAK激酶抑制剂的制备与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
TW201837045A (zh) * 2016-12-20 2018-10-16 瑞典商阿斯特捷利康公司 胺基-三唑并吡啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
JP2022534261A (ja) 2022-07-28
EP3976624A1 (en) 2022-04-06
TW202110849A (zh) 2021-03-16
BR112021023824A8 (pt) 2023-02-28
JP7696834B2 (ja) 2025-06-23
AR119018A1 (es) 2021-11-17
WO2020238900A1 (en) 2020-12-03
US20220242884A1 (en) 2022-08-04
AU2020281332B2 (en) 2026-04-02
MX2021014455A (es) 2022-01-06
AU2020281332A8 (en) 2021-11-18
CA3137598A1 (en) 2020-12-03
BR112021023824A2 (pt) 2022-01-04
CN113924305A (zh) 2022-01-11
KR20220027062A (ko) 2022-03-07
EP3976624A4 (en) 2023-06-14
AU2020281332A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
TWI899080B (zh) Ｄｎａ依賴性蛋白激酶抑制劑
US20220340581A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
CN114394966B (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
AU2020217339B2 (en) Salts of Pl3K inhibitor and processes for their preparation
US10800779B2 (en) Heterocyclic compounds as LSD1 inhibitors
US10858365B2 (en) Triazolo-pyrimidine compounds and uses thereof
KR102430144B1 (ko) BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
JP2024050653A (ja) Ｅｒｂｂ受容体阻害剤
US9447101B2 (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
JP5581390B2 (ja) Ａｋｔ阻害剤
JP6437452B2 (ja) Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
EP2845856A1 (en) Pyrimidinones as PI3K inhibitors
TWI626241B (zh) ３環性吡咯並吡啶化合物及ｊａｋ阻斷劑
KR102961371B1 (ko) Dna-의존적 단백질 키나제 억제제
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
RU2835434C2 (ru) Ингибитор ДНК-зависимой протеинкиназы
HK40060710A (en) Dna-dependent protein kinase inhibitor
WO2026041008A1 (en) Maleic acid derivatives and uses thereof
EA046406B1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
HK40037090B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases